标题
Targeted therapy for osteosarcoma: a review
作者
关键词
-
出版物
JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY
Volume -, Issue -, Pages -
出版商
Springer Science and Business Media LLC
发表日期
2023-02-20
DOI
10.1007/s00432-023-04614-4
参考文献
相关参考文献
注意:仅列出部分参考文献,下载原文获取全部文献信息。- Pazopanib in Patients with Osteosarcoma Metastatic to the Lung: Phase 2 Study Results and the Lessons for Tumor Measurement
- (2022) Paul Frankel et al. Journal of Oncology
- Osteosarcoma: A Surveillance, Epidemiology, and End Results program‐based analysis from 1975 to 2017
- (2022) Sarah Cole et al. CANCER
- Taking the Myc out of cancer: toward therapeutic strategies to directly inhibit c-Myc
- (2021) Sarah K. Madden et al. Molecular Cancer
- Predictive model for the 5-year survival status of osteosarcoma patients based on the SEER database and XGBoost algorithm
- (2021) Jiuzhou Jiang et al. Scientific Reports
- MDM2 Amplified Sarcomas: A Literature Review
- (2021) Raf Sciot Diagnostics
- Safety, anti-tumor activity, and biomarker analysis in a phase 1 trial of the once-daily Wee1 inhibitor adavosertib (AZD1775) in patients with advanced solid tumors
- (2021) Naoko Takebe et al. CLINICAL CANCER RESEARCH
- Angiopoietin inhibitors: A review on targeting tumor angiogenesis
- (2021) Digna Parmar et al. EUROPEAN JOURNAL OF PHARMACOLOGY
- Current status and novel strategy of CML
- (2021) Kiyomi Morita et al. INTERNATIONAL JOURNAL OF HEMATOLOGY
- Cyclin-Dependent Kinases (CDK) and Their Role in Diseases Development–Review
- (2021) Paweł Łukasik et al. INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
- Advances in targeted therapy for osteosarcoma based on molecular classification
- (2021) Yingqian Chen et al. PHARMACOLOGICAL RESEARCH
- Update on Osteosarcoma
- (2021) Rebekah Belayneh et al. Current Oncology Reports
- Rhaponticin suppresses osteosarcoma through the inhibition of PI3K-Akt-mTOR pathway
- (2021) Suresh Mickymaray et al. SAUDI JOURNAL OF BIOLOGICAL SCIENCES
- The Role of IGF/IGF-IR-Signaling and Extracellular Matrix Effectors in Bone Sarcoma Pathogenesis
- (2021) George N. Tzanakakis et al. Cancers
- Targeting the VEGF Pathway in Osteosarcoma
- (2021) Tarek Assi et al. Cells
- Assessment of Efficiency and Safety of Apatinib in Advanced Bone and Soft Tissue Sarcomas: A Systematic Review and Meta-Analysis
- (2021) Zuoyao Long et al. Frontiers in Oncology
- Combination of CDK4/6 and mTOR Inhibitors Suppressed Doxorubicin-resistant Osteosarcoma in a Patient-derived Orthotopic Xenograft Mouse Model: A Translatable Strategy for Recalcitrant Disease
- (2021) HIROMICHI OSHIRO et al. ANTICANCER RESEARCH
- Current research progress in targeted anti‐angiogenesis therapy for osteosarcoma
- (2021) Yun Liu et al. CELL PROLIFERATION
- IGF-1 and IGFBP-3 in Inflammatory Cachexia
- (2021) Ana Isabel Martín et al. INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
- Discovery of ZN-c3, a Highly Potent and Selective Wee1 Inhibitor Undergoing Evaluation in Clinical Trials for the Treatment of Cancer
- (2021) Peter Q. Huang et al. JOURNAL OF MEDICINAL CHEMISTRY
- Receptor tyrosine kinases and cancer: oncogenic mechanisms and therapeutic approaches
- (2021) Punit Saraon et al. ONCOGENE
- New frontiers against sorafenib resistance in renal cell carcinoma: From molecular mechanisms to predictive biomarkers
- (2021) Yu He et al. PHARMACOLOGICAL RESEARCH
- Apatinib plus ifosfamide and etoposide for relapsed or refractory osteosarcoma: A retrospective study in two centres
- (2021) Lu Xie et al. Oncology Letters
- Research models and mesenchymal/epithelial plasticity of osteosarcoma
- (2021) Xiaobin Yu et al. Cell and Bioscience
- TP53 in Biology and Treatment of Osteosarcoma
- (2021) Kamil Jozef Synoradzki et al. Cancers
- Abemaciclib is synergistic with doxorubicin in osteosarcoma pre-clinical models via inhibition of CDK4/6–Cyclin D–Rb pathway
- (2021) Deli Wang et al. CANCER CHEMOTHERAPY AND PHARMACOLOGY
- Treatment for liver cancer: From sorafenib to natural products
- (2021) Shuli Man et al. EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY
- Inhibition of WEE1 Is Effective in TP53- and RAS-Mutant Metastatic Colorectal Cancer: A Randomized Trial (FOCUS4-C) Comparing Adavosertib (AZD1775) With Active Monitoring
- (2021) Jenny F. Seligmann et al. JOURNAL OF CLINICAL ONCOLOGY
- Osteosarcoma: An Evolving Understanding of a Complex Disease
- (2021) John H. Alexander et al. JOURNAL OF THE AMERICAN ACADEMY OF ORTHOPAEDIC SURGEONS
- Circulating tumor DNA-guided treatment with pertuzumab plus trastuzumab for HER2-amplified metastatic colorectal cancer: a phase 2 trial
- (2021) Yoshiaki Nakamura et al. NATURE MEDICINE
- Recent Advances of WEE1 Inhibitors and Statins in Cancers With p53 Mutations
- (2021) Xiangbing Meng et al. Frontiers in Medicine
- Review on Epidermal Growth Factor Receptor (EGFR) Structure, Signaling Pathways, Interactions, and Recent Updates of EGFR Inhibitors
- (2020) Dima A. Sabbah et al. CURRENT TOPICS IN MEDICINAL CHEMISTRY
- Phase IB/II Trial of Lenvatinib Plus Pembrolizumab in Patients With Advanced Renal Cell Carcinoma, Endometrial Cancer, and Other Selected Advanced Solid Tumors
- (2020) Matthew H. Taylor et al. JOURNAL OF CLINICAL ONCOLOGY
- Cabozantinib in patients with advanced Ewing sarcoma or osteosarcoma (CABONE): a multicentre, single-arm, phase 2 trial
- (2020) Antoine Italiano et al. LANCET ONCOLOGY
- Evolving concepts in HER2 evaluation in breast cancer: heterogeneity, HER2-low carcinomas and beyond
- (2020) Caterina Marchiò et al. SEMINARS IN CANCER BIOLOGY
- The role of autophagy in resistance to targeted therapies
- (2020) Luigi Mele et al. CANCER TREATMENT REVIEWS
- Cyclin E1 is a prognostic biomarker and potential therapeutic target in osteosarcoma
- (2020) Ran Wei et al. JOURNAL OF ORTHOPAEDIC RESEARCH
- Piceatannol Suppresses the Proliferation and Induced Apoptosis of Osteosarcoma Cells Through PI3K/AKT/mTOR Pathway
- (2020) Bin Wang et al. Cancer Management and Research
- Tyrosine Kinase Inhibitors in Cancer: Breakthrough and Challenges of Targeted Therapy
- (2020) Charles Pottier et al. Cancers
- Pharmacogenetics for severe adverse drug reactions induced by molecular‐targeted therapy
- (2020) Chihiro Udagawa et al. CANCER SCIENCE
- Down‐regulation of PDGFRβ suppresses invasion and migration in osteosarcoma cells by influencing epithelial–mesenchymal transition
- (2020) Sining Xing et al. FEBS Open Bio
- Aurora-B Promotes Osteosarcoma Cell Growth and Metastasis Through Activation of the NPM1/ERK/NF-κβ/MMPs Axis
- (2020) Honghai Song et al. Cancer Management and Research
- Molecular Biology of Osteosarcoma
- (2020) Anna M. Czarnecka et al. Cancers
- Clinical efficiency of epigenetic drugs therapy in bone malignancies
- (2020) Filomena de Nigris et al. BONE
- The next tier of EGFR resistance mutations in lung cancer
- (2020) Hannah L. Tumbrink et al. ONCOGENE
- Pembrolizumab in Combination with Axitinib as First-Line Treatment for Patients with Renal Cell Carcinoma (RCC): Evidence to Date
- (2020) Vincent Chau et al. Cancer Management and Research
- Aurora-B knockdown inhibits osteosarcoma metastasis by inducing autophagy via the mTOR/ULK1 pathway
- (2020) Xin Wu et al. Cancer Cell International
- Overactivation of the IGF signalling pathway in osteosarcoma: a potential therapeutic target?
- (2020) Baptiste Ameline et al. Journal of Pathology Clinical Research
- Targeting mutant TP53 as a potential therapeutic strategy for the treatment of osteosarcoma
- (2019) Fan Tang et al. JOURNAL OF ORTHOPAEDIC RESEARCH
- A Phase 2 Study of Alisertib in Children with Recurrent/Refractory Solid Tumors or Leukemia: Children's Oncology Group Phase 1 and Pilot Consortium ADVL0921)
- (2019) Yael P. Mosse et al. CLINICAL CANCER RESEARCH
- Clinical genomic sequencing of pediatric and adult osteosarcoma reveals distinct molecular subsets with potentially targetable alterations
- (2019) Yoshiyuki Suehara et al. CLINICAL CANCER RESEARCH
- Cancer drug resistance: A fleet to conquer
- (2019) Showket Hussain et al. JOURNAL OF CELLULAR BIOCHEMISTRY
- Randomized Double-Blind Phase II Study of Regorafenib in Patients With Metastatic Osteosarcoma
- (2019) Lara E. Davis et al. JOURNAL OF CLINICAL ONCOLOGY
- Targeting mTOR for cancer therapy
- (2019) Hui Hua et al. Journal of Hematology & Oncology
- Genome-wide CRISPR-Cas9 screen reveals selective vulnerability of ATRX-mutant cancers to WEE1 inhibition
- (2019) Junbo Liang et al. CANCER RESEARCH
- CSN5 controls the growth of osteosarcoma via modulating the EGFR/PI3K/Akt axis
- (2019) Zongmiao Wan et al. EXPERIMENTAL CELL RESEARCH
- The Combination of Olaratumab with Doxorubicin and Cisplatinum Regresses a Chemotherapy-Resistant Osteosarcoma in a Patient-Derived Orthotopic Xenograft Mouse Model
- (2019) Takashi Higuchi et al. Translational Oncology
- ATRX In-Frame Fusion Neuroblastoma Is Sensitive to EZH2 Inhibition via Modulation of Neuronal Gene Signatures
- (2019) Zulekha A. Qadeer et al. CANCER CELL
- Precision medicine by designer interference peptides: applications in oncology and molecular therapeutics
- (2019) Anabel Sorolla et al. ONCOGENE
- Caveolin-1 Expression Together with VEGF can be a Predictor for Lung Metastasis and Poor Prognosis in Osteosarcoma
- (2019) Fatma El-Zahraa Ammar Mohamed et al. PATHOLOGY & ONCOLOGY RESEARCH
- WEE1 kinase inhibitor AZD1775 induces CDK1 kinase-dependent origin firing in unperturbed G1- and S-phase cells
- (2019) Tatiana N. Moiseeva et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Phase I Clinical Trial of the Wee1 Inhibitor Adavosertib (AZD1775) with Irinotecan in Children with Relapsed Solid Tumors. A COG Phase I Consortium Report (ADVL1312)
- (2019) Kristina A. Cole et al. CLINICAL CANCER RESEARCH
- Expression and therapeutic implications of cyclin-dependent kinase 4 (CDK4) in osteosarcoma
- (2018) Yubing Zhou et al. BIOCHIMICA ET BIOPHYSICA ACTA-MOLECULAR BASIS OF DISEASE
- Does ATRX germline variation predispose to osteosarcoma? Three additional cases of osteosarcoma in two ATR-X syndrome patients
- (2018) Julien Masliah-Planchon et al. EUROPEAN JOURNAL OF HUMAN GENETICS
- The PARP inhibitor olaparib potentiates the effect of the DNA damaging agent doxorubicin in osteosarcoma
- (2018) Hye Jeong Park et al. JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH
- The cyclin-dependent kinase inhibitor flavopiridol (alvocidib) inhibits metastasis of human osteosarcoma cells
- (2018) Loredana Zocchi et al. Oncotarget
- Genome-Informed Targeted Therapy for Osteosarcoma
- (2018) Leanne C Sayles et al. Cancer Discovery
- Identification of a novel gene fusion in ALT positive osteosarcoma
- (2018) Emily Mason-Osann et al. Oncotarget
- Response to Pazopanib in Patients With Relapsed Osteosarcoma
- (2018) Kunal R. Elete et al. JOURNAL OF PEDIATRIC HEMATOLOGY ONCOLOGY
- Efficacy and safety of regorafenib in adult patients with metastatic osteosarcoma: a non-comparative, randomised, double-blind, placebo-controlled, phase 2 study
- (2018) Florence Duffaud et al. LANCET ONCOLOGY
- A phase II trial evaluating the feasibility of adding bevacizumab to standard osteosarcoma therapy
- (2017) Fariba Navid et al. INTERNATIONAL JOURNAL OF CANCER
- MONARCH 3: Abemaciclib As Initial Therapy for Advanced Breast Cancer
- (2017) Matthew P. Goetz et al. JOURNAL OF CLINICAL ONCOLOGY
- Fusions in solid tumours: diagnostic strategies, targeted therapy, and acquired resistance
- (2017) Alison M. Schram et al. Nature Reviews Clinical Oncology
- Apatinib promotes autophagy and apoptosis through VEGFR2/STAT3/BCL-2 signaling in osteosarcoma
- (2017) Kuisheng Liu et al. Cell Death & Disease
- SPC24 promotes osteosarcoma progression by increasing EGFR/MAPK signaling
- (2017) Jun Sheng et al. Oncotarget
- mTOR signaling in osteosarcoma: Oncogenesis and therapeutic aspects (Review)
- (2016) Kai Hu et al. ONCOLOGY REPORTS
- Targeting WEE1 Kinase in Cancer
- (2016) Christopher J. Matheson et al. TRENDS IN PHARMACOLOGICAL SCIENCES
- The emerging roles and therapeutic potential of cyclin-dependent kinase 11 (CDK11) in human cancer
- (2016) Yubing Zhou et al. Oncotarget
- Generation of Osteosarcomas from a Combination of Rb Silencing and c-Myc Overexpression in Human Mesenchymal Stem Cells
- (2016) Jir-You Wang et al. Stem Cells Translational Medicine
- Impact of MYC in regulation of tumor cell metabolism
- (2015) Therese Wahlström et al. Biochimica et Biophysica Acta-Gene Regulatory Mechanisms
- Synergistic antiproliferative effect of imatinib and adriamycin in platelet-derived growth factor receptor-expressing osteosarcoma cells
- (2015) Sayaka I. Yamaguchi et al. CANCER SCIENCE
- Trastuzumab enhanced the cytotoxicity of Vγ9Vδ2 T cells against zoledronate-sensitized osteosarcoma cells
- (2015) Meng Liu et al. INTERNATIONAL IMMUNOPHARMACOLOGY
- EGFR is not a major driver for osteosarcoma cell growth in vitro but contributes to starvation and chemotherapy resistance
- (2015) Florian Sevelda et al. JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH
- Sorafenib and everolimus for patients with unresectable high-grade osteosarcoma progressing after standard treatment: a non-randomised phase 2 clinical trial
- (2015) Giovanni Grignani et al. LANCET ONCOLOGY
- Improved Overall Survival in Melanoma with Combined Dabrafenib and Trametinib
- (2015) Caroline Robert et al. NEW ENGLAND JOURNAL OF MEDICINE
- Exome sequencing of osteosarcoma reveals mutation signatures reminiscent of BRCA deficiency
- (2015) Michal Kovac et al. Nature Communications
- Cyclin-dependent kinase 2 is an ideal target for ovary tumors with elevated cyclin E1 expression
- (2015) Liu Yang et al. Oncotarget
- SAR405838: An Optimized Inhibitor of MDM2-p53 Interaction That Induces Complete and Durable Tumor Regression
- (2014) S. Wang et al. CANCER RESEARCH
- Targeting the BRCA1/2 Tumor Suppressors
- (2014) Eliot Rosen et al. CURRENT DRUG TARGETS
- Temsirolimus combined with cisplatin or bevacizumab is active in osteosarcoma models
- (2014) Emmy D.G. Fleuren et al. INTERNATIONAL JOURNAL OF CANCER
- Aurora-A kinase: Potential tumor marker of osteosarcoma
- (2014) Xiaozhong Zhu et al. Journal of Cancer Research and Therapeutics
- Phase II study of cixutumumab in combination with temsirolimus in pediatric patients and young adults with recurrent or refractory sarcoma: A report from the children's oncology group
- (2014) Lars M. Wagner et al. PEDIATRIC BLOOD & CANCER
- Recurrent Somatic Structural Variations Contribute to Tumorigenesis in Pediatric Osteosarcoma
- (2014) Xiang Chen et al. Cell Reports
- Preclinical validation of Aurora kinases-targeting drugs in osteosarcoma
- (2013) E Tavanti et al. BRITISH JOURNAL OF CANCER
- VEGFR, RET, and RAF/MEK/ERK Pathway Take Part in the Inhibition of Osteosarcoma MG63 Cells with Sorafenib Treatment
- (2013) Jiong Mei et al. CELL BIOCHEMISTRY AND BIOPHYSICS
- Dual CDK4/CDK6 Inhibition Induces Cell-Cycle Arrest and Senescence in Neuroblastoma
- (2013) J. Rader et al. CLINICAL CANCER RESEARCH
- The Combination of Sorafenib and Everolimus Abrogates mTORC1 and mTORC2 Upregulation in Osteosarcoma Preclinical Models
- (2013) Y. Pignochino et al. CLINICAL CANCER RESEARCH
- Phase 2 trial of cixutumumab in children, adolescents, and young adults with refractory solid tumors: A report from the Children's Oncology Group
- (2013) Brenda Weigel et al. PEDIATRIC BLOOD & CANCER
- Wee1 Inhibition by MK-1775 Leads to Tumor Inhibition and Enhances Efficacy of Gemcitabine in Human Sarcomas
- (2013) Jenny M. Kreahling et al. PLoS One
- Phase II Trial of Trastuzumab in Combination With Cytotoxic Chemotherapy for Treatment of Metastatic Osteosarcoma With Human Epidermal Growth Factor Receptor 2 Overexpression: A Report From the Children's Oncology Group
- (2012) David Ebb et al. JOURNAL OF CLINICAL ONCOLOGY
- c-Myc Overexpression Promotes Osteosarcoma Cell Invasion Via Activation of MEK-ERK Pathway
- (2012) Gang Han et al. ONCOLOGY RESEARCH
- A phase II trial of sorafenib in relapsed and unresectable high-grade osteosarcoma after failure of standard multimodal therapy: an Italian Sarcoma Group study
- (2011) G. Grignani et al. ANNALS OF ONCOLOGY
- WEE1 inhibition sensitizes osteosarcoma to radiotherapy
- (2011) Jantine PosthumaDeBoer et al. BMC CANCER
- Anti-EGFR Antibody Cetuximab Enhances the Cytolytic Activity of Natural Killer Cells toward Osteosarcoma
- (2011) J. H. W. Pahl et al. CLINICAL CANCER RESEARCH
- Phase II Study of the Mammalian Target of Rapamycin Inhibitor Ridaforolimus in Patients With Advanced Bone and Soft Tissue Sarcomas
- (2011) Sant P. Chawla et al. JOURNAL OF CLINICAL ONCOLOGY
- Cyclin E1 Is Amplified and Overexpressed in Osteosarcoma
- (2011) William W. Lockwood et al. JOURNAL OF MOLECULAR DIAGNOSTICS
- The Cyclin-Dependent Kinase Inhibitor SCH 727965 (Dinacliclib) Induces the Apoptosis of Osteosarcoma Cells
- (2011) W. Fu et al. MOLECULAR CANCER THERAPEUTICS
- Insulin-like growth factor-I receptor tyrosine kinase inhibitor cyclolignan picropodophyllin inhibits proliferation and induces apoptosis in multidrug resistant osteosarcoma cell lines
- (2009) Z. Duan et al. MOLECULAR CANCER THERAPEUTICS
- Role of platelet-derived growth factors in physiology and medicine
- (2008) J. Andrae et al. GENES & DEVELOPMENT
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExploreCreate your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create Now